Macquarie Group’s TriSalus Life Sciences TLSI Stock Holding History

Macquarie Group’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-291	Closed	-$3	–	2139
2024 Q1	$3	Buy	+291	New	+$2.69K	﹤0.01%	1839

Other funds holding TLSI

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

CWM

Connecticut Wealth Management Farmington, Connecticut $2.39B AUM 17.35% 1-Year Est. Return

Macquarie Group's TLSI Position: Q2 2024 in Review

Macquarie Group sold out of TriSalus Life Sciences (TLSI) in Q2 2024, closing a stake of 291 shares — an estimated $3 sold.

Macquarie Group first reported a position in TLSI in Q1 2024 and held it in 1 quarter. The position peaked at $3 in Q1 2024. 28 funds tracked by Wall St. Rank hold TLSI as of Q2 2024.

Macquarie Group reported no remaining TriSalus Life Sciences position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 291 TriSalus Life Sciences shares in Q2 2024, an estimated $3.
Macquarie Group first reported a position in TriSalus Life Sciences in Q1 2024 and held it in 1 quarter.
Macquarie Group's TriSalus Life Sciences position peaked at $3 in Q1 2024.
28 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.